Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.57 |
| ▸ | CTSK | P43235 | 4/20 | 0.50 |
| ▸ | CTSS | P25774 | 4/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7438422 | 1.00 | TRPA1 (0.57) | TRPA1CTSKCTSSKLK5PPARG | |
| SCHEMBL8284734 | 0.85 | CTSK (0.48) | TRPA1CTSKCTSSKLK5PPARG | |
| SCHEMBL7437423 | 0.85 | PPARA (0.47) | TRPA1CTSKCTSSKLK5PPARG | |
| SCHEMBL16235262 | 0.85 | TRPA1 (0.58) | TRPA1CTSKCTSSCA2MEN1 | |
| SCHEMBL14087330 | 0.85 | CTSK (0.48) | TRPA1CTSKCTSSKLK5PPARG | |
| SCHEMBL23619006 | 0.84 | PPARA (0.48) | CTSKCTSSPPARGPPARAPPARD | |
| SCHEMBL15432503 | 0.84 | PPARA (0.48) | CTSKCTSSPPARGPPARAPPARD | |
| SCHEMBL3740636 | 0.84 | PPARA (0.48) | CTSKCTSSPPARGPPARAPPARD | |
| SCHEMBL8379726 | 0.82 | TRPA1 (0.52) | TRPA1CTSKCTSSPPARG | |
| SCHEMBL8379733 | 0.82 | TRPA1 (0.52) | TRPA1CTSKCTSSPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433248-B1 | PHYSICAL FORM OF A SGR MODULATOR | ASTRAZENECA AB (SE) | 2022-06-22 | — | — | EP | disclosed |
| CN-109415348-B | Novel physical forms of SGR modulators | 阿斯利康(瑞典)有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-10407404-B2 | Physical form of a SGR modulator | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| EP-3197878-B1 | 1-ALKYL-6-OXO-1,6-DIHYDROPYRIDIN-3-YL COMPOUNDS AND USE AS SGRM MODULATORS | ASTRAZENECA AB (SE) | 2019-07-24 | — | — | EP | disclosed |
| US-20190106402-A1 | Physical Form Of A SGR Modulator | STA PHARMACEUTICAL R&D CO., LTD (CN) | 2019-04-11 | — | — | US | disclosed |
| US-10196374-B2 | 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as SGRM modulators | ASTRAZENECA AB (SE) | 2019-02-05 | — | — | US | disclosed |
| US-20170298041-A1 | 1-ALKYL-6-OXO-1,6-DIHYDROPYRIDIN-3-YL COMPOUNDS AND USE AS SGRM MODULATORS | ASTRAZENECA AB (SE) | 2017-10-19 | — | — | US | disclosed |
| WO-2017161518-A1 | NEW PHYSICAL FORM | ASTRAZENECA AB (SE) | 2017-09-28 | — | — | WO | disclosed |
| US-7423058-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-7205330-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2007-04-17 | — | — | US | disclosed |
| WO-2005085275-A1 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | HAVCR2, RNASE1, SERPINB1 | TRPA1 3117/4885CTSK 275/4885CTSS 103/4885 |
| US-20190106402-A1 | Physical Form Of A SGR Modulator | FIS1, CHRM3, NDUFB7 | TRPA1 2783/4885CTSK 1252/4885CTSS 1014/4885 |
| US-20170298041-A1 | 1-ALKYL-6-OXO-1,6-DIHYDROPYRIDIN-3-YL COMPOUNDS AND USE AS SGRM MODULATORS | ADRM1, GRM1, GRM6 | TRPA1 4446/4885CTSK 2072/4885CTSS 1844/4885 |
| US-10407404-B2 | Physical form of a SGR modulator | FIS1, CHRM3, NDUFB7 | TRPA1 2783/4885CTSK 1252/4885CTSS 1014/4885 |
| US-10196374-B2 | 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as SGRM modulators | ADRM1, GRM1, GRM6 | TRPA1 4446/4885CTSK 2072/4885CTSS 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.